Related Experiment Video
Updated: Dec 30, 2025
Merkel Cell Polyomavirus Infection and Detection
Published on: February 7, 2019
Immunobiology of Merkel cell carcinoma
Mahtab Samimi1,2, Thibault Kervarrec2,3, Antoine Touze2
1Dermatology Department, University Hospital of Tours.
Purpose Of Review:
Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer, which is associated in 80% of cases with the Merkel cell polyomavirus (MCPyV). Advanced stages respond to immune checkpoint inhibitors in 50% of cases. Major issues remain unanswered regarding its oncogenesis and optimal treatment.
Recent Findings:
MCPyV-negative and MCPyV-positive MCCs have been hypothesized to derive from distinct cells, although the cell of origin remains a matter of debate. The crucial role the MCPyV small T oncoprotein was recently confirmed by its ability to inactivate p53, together with its contribution to the metastatic progression. In advanced cases, tumoral microenvironment may adequately predict responses to immunotherapies, and several mechanisms of primary and secondary resistance have been investigated.
Summary:
Identifying the mechanisms of oncogenesis allow experimentation of new therapeutic targets, which remain mandatory even at the era of immunotherapies. Although new insights in the mechanisms of primary and secondary resistance pave the way for development of further immunotherapy strategies, neoadjuvant strategies may challenge our whole approach of the disease.
Insights
Merkel cell carcinoma (MCC), a rare skin cancer linked to Merkel cell polyomavirus (MCPyV), requires further research into its origins and treatments. Understanding oncogenesis and resistance mechanisms is key to developing new therapies.
Area of Science:
- Oncology
- Virology
- Dermatology
Background:
- Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer.
- Eighty percent of MCC cases are associated with Merkel cell polyomavirus (MCPyV).
- Advanced MCC responds to immune checkpoint inhibitors in 50% of cases.
Purpose of the Study:
- To review current understanding of MCC oncogenesis.
- To explore treatment strategies for advanced MCC.
- To investigate mechanisms of resistance to immunotherapy.
Main Methods:
- Review of recent findings on MCPyV's role in MCC.
- Analysis of the tumor microenvironment's predictive value for immunotherapy response.
- Investigation into primary and secondary resistance mechanisms.
Main Results:
- MCPyV small T oncoprotein inactivates p53 and promotes metastasis.
- Tumor microenvironment characteristics can predict immunotherapy response.
- Mechanisms of primary and secondary resistance to treatment are being elucidated.
Conclusions:
- Identifying oncogenesis mechanisms is crucial for developing novel therapeutic targets.
- Insights into resistance mechanisms can guide further immunotherapy strategies.
- Neoadjuvant strategies may significantly alter the approach to MCC treatment.
More Related Videos
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:27Tumor Immunotherapy
01:31Immunoglobulin-like Cell Adhesion Molecules
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...